Expression of ADAM12 is low in most normal tissues, but is markedly increased in numerous human cancers, including breast carcinomas. We have previously shown that overexpression of ADAM12 accelerates tumor progression in a mouse model of breast cancer (PyMT). In the present study, we found that ADAM12 deficiency reduces breast tumor progression in the PyMT model. However, the catalytic activity of ADAM12 appears to be dispensable for its tumor-promoting effect. Interestingly, we demonstrate that ADAM12 endogenously expressed in tumor-associated stroma in the PyMT model does not influence tumor progression, but that ADAM12 expression by tumor cells is necessary for tumor progression in these mice. This finding is consistent with our observation that in human breast carcinoma ADAM12 is almost exclusively located in tumor cells and only rarely seen in the tumor-associated stroma. We hypothesized, however, that the tumorassociated stroma may stimulate ADAM12 expression in tumor cells, based on the fact that TGF-β1 stimulates ADAM12 expression and is a well-known growth factor released from tumor-associated stroma. TGF-β1 stimulation of ADAM12-negative Lewis lung tumor cells induced ADAM12 synthesis, and growth of these cells in vivo induced a >200-fold increase in ADAM12 expression.
Introduction
Breast cancer continues to be one of the leading causes of death among women in Western countries. Each year, close to 200,000 women are diagnosed with breast cancer in the United States, and, despite improved screening for early detection as well as improved treatment modalities, approximately 40,000 U.S. women die of the disease (1).
Tumors are composed not only of neoplastic cells, but also of stromal cells including myofibroblasts, angiogenic and inflammatory cells that reside in the extracellular matrix. Cell-cell and cell-matrix interactions between tumor cells, the surrounding stromal cells, and the extracellular matrix ignite cascades of molecular signals in and out of cells, modulating cell behavior and contributing to tumor progression (2) (3) (4) . Metalloproteases are among the key proteins associated with malignancy (4, 5) . One such metalloprotease, ADAM12 (Meltrin alpha), has recently been found to be a candidate breast cancer susceptibility gene (6) . ADAM12 is a member of the large ADAM family of transmembrane proteins and has several potentially important biological functions in cancer (reviewed in (7, 8)) . At the molecular level, ADAM12 can -as many other ADAMs (8, 9)-mediate proteolytic ectodomain shedding of growth factors and cell adhesion molecules (7, 8, 10) . Importantly, ADAM12 is also involved in nonproteolytic protein-protein interactions-e.g., it binds to integrins, syndecans, and transforming growth factor (TGF) β receptor II (TGFβRII) at the cell surface, and its intracellular tail associates with adaptors and signalling molecules (such as Grb2, Tks5, and Src kinases) (7, 8) .
In normal tissue, expression of ADAM12 is generally low; however, several studies have reported that the expression of ADAM12 is markedly increased in many human cancers, including breast (11) (12) (13) (14) (15) , liver (16) , bladder (17) , and lung (18, 19) carcinomas and glioblastomas (20) , and that the level of expression often relates to tumor stage. The potential use of ADAM12 as a biomarker for tumor progression was further evidenced by the finding that soluble ADAM12 in 4 urine from breast and bladder cancer patients correlates with disease stage (17, 21, 22) . We have previously demonstrated that overexpression of ADAM12 promotes tumor progression in the mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT) model (12) . This discovery correlates with the finding that ADAM12 deficiency reduces tumor progression in the TRAMP mouse model of prostate cancer (23) .
Here, we explored how endogenous ADAM12 impacts breast tumor progression. In particular, we investigated the role of ADAM12 localization in the stromal compartment versus the tumor compartment in promoting tumor progression. To answer this question, we established an in vivo model system to investigate whether ADAM12 produced by the stromal cells in mouse mammary-gland tumors influences tumor progression. The data demonstrate that ADAM12 produced by tumor cells promotes tumor progression whereas ADAM12 expressed by the tumorassociated stroma did not. Interestingly, however, we observed that TGF-β1, known to be produced by the tumor-associated stroma, influences expression of ADAM12 in the tumor cell compartment.
In addition, we observed that the proteolytic activity of ADAM12 appears to be dispensable for this tumor-promoting effect.
Thus, we hypothesize that the effect of ADAM12 -that is, increased proliferation and dedifferentiation could be mediated through enhanced TGF-β1 signalling provided by the surrounding stroma.
Materials and Methods
Mice. Male FVB/N-TgN(MMTV-PyMT)634Mul (Jackson Laboratory, Bar Harbor, ME) mice were mated with ADAM12 (Meltrin alpha)-deficient (ADAM12 -/-) female mice (24) that had been previously backcrossed for 9 generations into the FVB/N background. Male PyMT-ADAM12+/-offspring were mated with female ADAM12-/-mice to obtain PyMT-ADAM12-/-and littermate PyMT-ADAM12+/-mice. All animals analyzed in this study were females and examined as previously described (12) . Wild-type, ADAM12+/-, and ADAM12-/-mice on C57/Bl6 and FVB/N genetic backgrounds were used for injections of tumor cells. Cell lines (10 6 cells per mouse)
were injected subcutaneously into the right flank or into the mammary gland. Tumor size (length and width) was measured over time. Mice were sacrificed when the first tumor reached 1.2 cm 2 .
One hour before sacrifice, 5-bromo-2'-deoxyuridine (BrdU; 50 µg/g body weight) was injected intraperitoneally (i.p.), subsequently mice were anesthetized by i.p. administration of a 1:1 mixture of Dormicum and Hypnorm. Tumors were removed and the mice were perfusion fixed with cold PBS followed by cold 4% paraformaldehyde. Lungs were removed, fixed and cryoembedded as described (25) . Tumor burden was calculated as the percentage of tumor mass/mouse weight.
Tumor volume was estimated according to the formula; V(tumor) = πlw 2 /6 (26 To generate primary tumor cells, tumors from 8-10-week-old PyMT-ADAM12-/-mice and their littermate controls were harvested, minced into small pieces, and tumor cells isolated as described (27) . Freshly isolated cells were plated on collagen type I (PureCol from Advanced Biomatrix, San Diego, CA) and grown for 24 hours in DMEM, penicillin/streptomycin, and 10%
FBS. Vital and adherent cells were harvested and immediately frozen or used for immortalization.
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To generate immortalized PyMT cell lines, pBABE-PyMT (Addgene, Cambridge, MA (plasmid 22305)) (27) was retrovirally transduced as described previously (28) into primary tumor cells isolated from PyMT-ADAM12+/-and PyMT-ADAM12-/-mice. Cells were kept in DMEM with 50 µg/mL hygromycin B. The established cell line deficient in ADAM12 expression was termed PyMT-A12null, whereas the control cell line expressing ADAM12 was termed PyMTA12hz (hz for heterozygous). PyMT-A12null cells stably expressing human ADAM12-L lacking the cytoplasmic tail (hADAM12Δcyt), hADAM12Δcyt with a catalytic site mutation (hADAM12Δcyt-E351Q), or vector control were generated by retroviral transduction as described (12) . The ADAM12-E351Q mutant was previously shown to be proteolytic inactive (29) (30) (31) . The cytoplasmic tail of ADAM12 retains ectopically expressed ADAM12 in the trans-Golgi network;
hence, to ensure accurate ADAM12 expression at the plasma membrane, hADAM12Δcyt was used (32) . The established cell lines were designated PyMT-A12, PyMT-A12EQ, and PyMT-VC, respectively, and kept in DMEM containing 4 µg/mL puromycin and 50 µg/mL hygromycin B.
Staining and analysis of mouse tissue and cells. Mammary-gland tumors were obtained from PyMT-ADAM12-/-mice and PyMT-ADAM12+/-littermates and processed for histological analysis as described (12, 33, 34) . Briefly, the histological evaluation was based on a four-stage classification scheme that includes hyperplasia, adenoma, and early and late carcinoma (34) . These stages are in agreement with the recommendations for classifications of mouse mammary tumor pathology (33) , but improved for the PyMT model (34) . Areas of early and late carcinoma as well as hyperplasia and adenoma areas were marked and the areas estimated by two independent observers as described (12, 34) . To evaluate cell proliferation, DNA synthesis was determined using TGTGGAAATGGCTATGTGGA-3´; reverse, 5´-CAGGTGGTAGCGTTACAGCA-3´). qPCR data were analyzed using the 2(-ΔΔC(t)) method (35) .
Reverse transcription-PCR (RT-PCR) and quantitative PCR (qPCR
Western blot. Western blots of cell lysates were performed as described previously (36) . (Table 1A ). In addition, specimens from breast resections of 61 patients who underwent conservation surgery for a breast lump at Turku University Hospital (Turku, Finland) were analyzed. To prepare macrosections, fresh surgical breast tissue was sliced at 5-mm intervals through the specimen. Each tissue slice was visualized with mammography to ensure excision of the whole tumor area. All tissue slices were then separately and in sequence fixed in formalin, embedded in paraffin in 5 x 5 cm macroblocks, cut into 5-µm sections, and H&E stained. From these macroblocks, 1-3 representative areas were excised, re-embedded in paraffin, and 5-μm sections cut for staining.
From the same hospital, normal breast tissue was obtained from 10 patients who underwent aesthetic breast-reduction surgery. The experimental use of the surgical specimens was in accordance with the hospital ethical guidelines of Turku University Hospital.
ADAM12 immunohistochemistry of human breast tissue. ADAM12 immunostaining was performed as described earlier (11, 12) , using either polyclonal antibodies to human ADAM12 (rb109, rb116, or rb122; 1:250 dilution) or normal rabbit IgG fraction (10 µg/mL) prepared in PBS. Statistical analysis. Statistical analysis was done using Kaplan-Meier to determine tumorfree periods, and the log-rank test, the Wilcoxon Signed-Rank test, and the Student's t test for comparing two independent groups. P < 0.05 was considered statistically significant.
Results and Discussion
ADAM12 deficiency delays PyMT-induced mammary tumorigenesis. To elucidate the role of ADAM12 in breast cancer, we analyzed the effect of ADAM12 deficiency on mammarytumor growth in the PyMT mouse model of breast cancer. ADAM12-deficient mice were cross-bred with MMTV-PyMT mice and analyzed for tumor onset and progression. PyMT-ADAM12-/-mice developed palpable breast tumors at a significantly slower rate than did PyMT-ADAM12+/-mice (Fig. 1A) . In the PyMT-ADAM12-/-cohort, tumors in female offspring appeared at day 73±12 (mean ±SD), whereas PyMT-ADAM12+/-mice developed tumors by day 61±8. The tumor burden was significantly decreased in PyMT-ADAM12-/-mice at 12 weeks of age, as compared with agematched PyMT-ADAM12+/-mice (Fig. 1B) . Histopathological examination of H&E-stained sections of breast tissue was performed to analyze tumor grade (degree of differentiation), as described (12, 34) . We evaluated the percentage of early and late carcinoma as well as hyperplasia and adenoma areas within the mammary-gland tumors (34) and found a significant reduction of areas of early and late carcinoma in the tumors from PyMT-ADAM12-/-mice as compared with
PyMT-ADAM12+/-mice ( Fig. 1 C and D) . In addition to developing spontaneous breast tumors, PyMT mice have a high incidence of lung metastasis. Thus, the percentage of mice bearing at least one tumor nodule was determined by histological examinations as exemplified in Figure 1E . The incidence of lung metastasis was 55% in PyMT-ADAM12hz mice (6/11) and 9% in PyMTADAM12null mice (1/11) (Fig. 1F) . Taken together, these data demonstrate that ADAM12 significantly influences tumor initiation and progression, confirming and extending previous reports (12, 15, 23) .
ADAM12 affects the proliferative capacity of PyMT tumor cells. Based on previous studies proposing that ADAM12 may influence tumor cell proliferation (13, 20, 38, 39) , we hypothesized that endogenous ADAM12 in the PyMT mouse model regulates cancer cell proliferation. Therefore, BrdU incorporation was assessed in PyMT-ADAM12-/-and PyMT-ADAM12+/-tumors. A significant decrease in tumor cell proliferation was observed in the PyMT-ADAM12-/-tumors compared with PyMT-ADAM12+/-tumors ( Fig. 2A) . To study the observed difference in tumor cell proliferation in more detail, tumor cells from both PyMT-ADAM12-/-and PyMT-ADAM12+/-mice were isolated, immortalized, and grown in vitro. Immunofluorescence staining using an antibody against cytokeratins confirmed that the immortalized PyMT-A12null and PyMT-A12hz cell lines were of epithelial origin (Supplemental Fig. 1A ). RT-PCR and Western blotting confirmed the endogenous expression of ADAM12 in PyMT-A12hz tumor cells and a lack of ADAM12 expression in the PyMT-A12null tumor cells ( Fig. 2B and C) . Next, the proliferative capacity of the two tumor cell lines was compared by in vitro and in vivo assays. The PyMTA12null tumor cells showed a significantly reduced proliferative capacity in vitro compared with PyMT-A12hz tumor cells (Fig. 2D) . Accordingly, when the PyMT-A12null and PyMT-A12hz cells were injected into the mammary gland of wild-type or ADAM12-/-mice, the PyMT-A12null cells grew significantly slower than the PyMT-A12hz tumor cells (Fig. 2E and F) . Although there is a significant difference between proliferation of PyMT-A12hz and PyMT-A12null tumor cells in vitro, we reason that the more pronounced difference in in vivo tumor cell growth relates to the tumor-stroma interactions. Similarly, PyMT-A12hz cells injected subcutaneously gave rise to significantly larger tumors compared to PyMT-A12null cells (Supplemental Fig. 1B) . Intriguing, we observed that orthotopic injection of the tumor cells gave rise to larger tumors when compared to (Fig. 2E,F 
resulting three new cell lines-PyMT-A12, PyMT-A12EQ, and PyMT-VC-were studied. Western blotting demonstrated that ADAM12 was expressed in both the PyMT-A12 and PyMT-A12EQ cells, but not in the PyMT-VC cells (Fig. 3A) . The proliferative capacity of the three tumor cell lines was compared by in vitro and in vivo assays. Interestingly, both PyMT-A12 and PyMT-A12EQ tumor cells showed a significantly increased proliferative capacity in vitro compared with PyMT-VC tumor cells ( Figure 3B) . However, the proliferative index between PyMT-A12 and PyMT-A12EQ tumor cells was not significantly different. The three cell lines were subsequently injected into the mammary gland (Fig. 3C) or subcutaneously in the right flank (Fig. 3D) (Fig. 3E) , suggesting that ADAM12 is not involved in ectodomain shedding and the consequent release of EGFR ligands, such as EGF and HB-EGF in these cell lines.
However, we found that both PyMT-A12 and PyMT-A12EQ tumor cells exhibited higher levels of phosphorylated Akt compared to PyMT-VC tumor cells (Fig. 3F) , indicating that ADAM12 independent of its proteolytic activity may stimulate Akt signaling to support tumor cell proliferation. Taken together, these results suggest that the effect of ADAM12 on tumor progression in the PyMT model system is not dependent on its proteolytic activity. Although these data contrast with the finding that ADAM12 positively correlates with the proliferative index in human glioblastomas and the ability to shed proheparin binding-EGF (20) , they substantiate the reports that ADAM10 and ADAM17 are the main sheddases of EGFR ligands (44, 45) . as well as full-length ADAM12-S has been previously shown to bind integrins (47) (48) (49) (50) (51) (52) (53) (54) and impair the function of β1-integrin, consequently altering the organization of the actin cytoskeleton and extracellular matrix (28). Moreover, the extracellular domains of ADAM12 interact with TGFβRII and contribute to TGFβ signaling (46) . Notably, Akt, which activation is increased in both PyMT-A12 and PyMT-A12EQ mutant cells as compared to control (Fig. 3F) , is a downstream target in both integrin and TGFβRII signaling cascades known to affect proliferation and survival (55, 56) .
While it remains to be elucidated whether ADAM12 interacts with these molecules in breast tumor cells in vivo, it is intriguing that deletion of both β1-integrin and focal adhesion kinase, a major mediator of integrin signaling, suppresses PyMT-mediated tumor initiation and progression in animal models (27, 57) .
Stromal ADAM12 does not influence tumor growth in PyMT-mediated breast tumors.
ADAM12 mRNA is endogenously expressed in α-smooth muscle actin (α-SMA)-positive stromal cells in the PyMT breast cancer model and in the W 10 prostate cancer model (23) . In addition, ADAM12 expression in stroma is required for prostate tumor progression. However, our data ( (Fig. 4A) . Next, to determine the role of ADAM12 produced by the stromalcell compartment on PyMT tumor progression, PyMT-A12hz and PyMT-A12null cells were injected into the mammary gland ( Fig. 4B and C) or subcutaneously ( Fig. 4D and E ADAM12 is produced by tumor cells in human breast cancer. The relevance of our findings to human breast carcinoma is significant. Previous studies of ADAM12 expression in breast carcinomas have reported that it is highly expressed in carcinoma cells but that it is not detected in the stroma (11, 12, 14, 17, 18) . To verify this conclusion, we analyzed the ADAM12 distribution pattern by immunohistochemistry in human breast carcinoma specimens from 805 cases, arranged in 6 separate tissue arrays. A total of almost 63% of the cases exhibited positive ADAM12 immunoreactivity of the tumor cells (Table 1A) in which macroblocks had been prepared (Supplemental Fig. 3) . Detailed semi-quantitative immunohistochemical analyses (Table 1B) demonstrated that ADAM12 immunoreactivity was found in 47% of IDC and 97% of ILC samples studied. Furthermore, areas containing ADH and/or DCIS in addition to tumor cells were selected (see insert in Supplemental Fig. 3A) . We observed ADAM12 immunoreactivity in 77% of the epithelial cells in ADH and 84% of epithelial cells in DCIS. Of all the tissue specimens that exhibited positive ADAM12 immunoreactivity, only the breast epithelial cells were found to be positive for ADAM12 (Fig. 5A and B) . In few cases, a few stromal cells exhibited positive staining for ADAM12 (data not shown). These data confirm previous observations that, in human breast cancer, ADAM12 expression is almost exclusively located in tumor cells, and only rarely seen in the tumor-associated stroma (11-13).
Tumor-associated stroma induces ADAM12 expression in the epithelium. The expression of ADAM12 is low in most normal tissues, but relatively high in many human cancers. 
including the breast cancer cell line MDA-MB-231 (61) . Hence, we analyzed whether tumorstromal interactions or the tumor-associated stroma could regulate the expression of ADAM12 in cells normally not expressing the protein, potentially through TGF-β1 action. For this purpose, we took advantage of Lewis Lung cells, which express no or low levels of ADAM12 in vitro (Fig. 6A) , and which are syngeneic with the ADAM12-deficient mouse strain. Initially, we demonstrated that stimulation of Lewis Lung cells with TGF-β1 in vitro increased the expression of ADAM12, as assessed by RT-PCR, qPCR, and Western Blot (Fig. 6B,C,D) . Subsequently, Lewis Lung cells were injected subcutaneously into wild-type, ADAM12+/-, or ADAM12-/-mice and, as expected, no difference in tumor growth was seen (Fig. 6E) . However, the ADAM12 transcript was >200-fold up-regulated in Lewis Lung tumors formed in ADAM12-/-mice compared with Lewis Lung cells grown in vitro (Fig. 6F) , indicating that the stroma compartment or tumor-stroma interaction initiate tumor cell expression of ADAM12. In comparison, the level of ADAM12 mRNA in the Lewis Lung tumor tissue in wild-type and ADAM12+/-mice was much higher than in tumors from ADAM12-/-mice (Fig. 6G) , suggesting that ADAM12 is expressed in the stroma compartment as also shown in Figure 4A . Immunohistochemistry staining of ADAM12 in Lewis Lung cells grown as subcutaneous tumors confirm the presence of ADAM12 protein in the tumor cells (Supplemental Fig. 4 ). These data support the hypothesis that tumor-associated stroma induces ADAM12 expression in tumor cells and they suggest the possibility that TGF-β1 may be one stromal factor that contributes to ADAM12 expression (46) .
To analyze if changes in tumor-associated stroma have the ability to influence expression of ADAM12 in human breast tissue, we analyzed the macroblocks from human breast cancer patients described above. These macroblocks enabled us to perform immunohistochemical evaluation of ADAM12 expression in extended areas of the surrounding tissue from 45 cases of invasive carcinomas. In particular, we were able to examine the TDLUs adjacent to the carcinomas in greater detail (Supplemental Fig. 3 ). ADAM12 immunostaining was clearly increased both in distribution and intensity in the TDLUs adjacent to the invasive tumor compared with the normal TDLUs from breast reductions (Fig. 5C and D) . Whereas 89% of epithelial cells in the TDLUs adjacent to invasive carcinomas were positive for ADAM12, only 28% in the normal TDLUs in breastreduction tissue showed positive ADAM12 immunostaining (Table 1C) . This result could imply that humoral factors (i.e., TGF-β1) from the malignant tumor or the tumor-associated stroma might influence expression of ADAM12 in the breast epithelium in the TDLUs adjacent to the malignant tumor. Indeed, a recent study demonstrated that TGF-β1 is up-regulated at the interface between the periphery of breast tumor tissue and normal adjacent tissue compared with normal tissue (62) .
Together, the data presented here strongly emphasize the importance of endogenous ADAM12 for efficient tumor development. Intriguingly, the pro-tumorigenic effect of ADAM12 appears to involve nonproteolytic mechanisms. Moreover, our data imply that the stroma may trigger ADAM12 expression in tumor cells and TDLUs adjacent to tumor cells, even though ADAM12 expression in the stroma is not important for tumor growth in the mouse models studied. Based on these findings, we propose that ADAM12 expression in tumor cells contributes to their proliferation and de-differentiation.
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